Search alternatives:
significant test » significance test (Expand Search), significant threat (Expand Search), significance tests (Expand Search)
larger decrease » marked decrease (Expand Search)
lower decrease » linear decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
test revealed » also revealed (Expand Search), results revealed (Expand Search)
Showing 81 - 100 results of 42,034 for search '(( significantly ((lower decrease) OR (larger decrease)) ) OR ( significant test revealed ))', query time: 1.65s Refine Results
  1. 81
    Comparison of pretreatment cephalometric variables between premolar extraction and mandibular third molar extraction groups.

    Comparison of pretreatment cephalometric variables between premolar extraction and mandibular third molar extraction groups. by Lijuan Liu (136685)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 82
    Demographic characteristics of study participants.

    Demographic characteristics of study participants. by Lijuan Liu (136685)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 83
    Results of Analysis of Co-variance (ANCOVA) for change in parameter predicted by treatment group with pre-treatment value as a covariate. * p < 0.05; ** p < 0.01.

    Results of Analysis of Co-variance (ANCOVA) for change in parameter predicted by treatment group with pre-treatment value as a covariate. * p < 0.05; ** p < 0.01. by Lijuan Liu (136685)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 84
    Comparison of treatment effects between premolar extraction and mandibular third molar extraction groups. * p < 0.05; ** p < 0.01.

    Comparison of treatment effects between premolar extraction and mandibular third molar extraction groups. * p < 0.05; ** p < 0.01. by Lijuan Liu (136685)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 85
    Intraoperative facial and intraoral photographs of the case with mandibular third molar extraction.

    Intraoperative facial and intraoral photographs of the case with mandibular third molar extraction. by Lijuan Liu (136685)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 86
    Pretreatment facial, intraoral photographs, and radiographs of the case with premolar tooth extraction.

    Pretreatment facial, intraoral photographs, and radiographs of the case with premolar tooth extraction. by Lijuan Liu (136685)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 87
    Pretreatment facial, intraoral photographs, and radiographs of the case with mandibular third molar extraction.

    Pretreatment facial, intraoral photographs, and radiographs of the case with mandibular third molar extraction. by Lijuan Liu (136685)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 88
    Significant differences (<i>p</i>s < .05) revealed by t-test (<i>n</i> = 1856) with demographic characteristics as dependent variables.

    Significant differences (<i>p</i>s < .05) revealed by t-test (<i>n</i> = 1856) with demographic characteristics as dependent variables. by Kun Qian (62517)

    Published 2020
    “…<p>Significant differences (<i>p</i>s < .05) revealed by t-test (<i>n</i> = 1856) with demographic characteristics as dependent variables.…”
    Save to List
    Saved in:
  9. 89
    The results of KEGG enrichment analysis (Annotation: Circles represent each pathway, and the redder the color, the larger the circle, and the more important it is).

    The results of KEGG enrichment analysis (Annotation: Circles represent each pathway, and the redder the color, the larger the circle, and the more important it is). by Lin Zhou (141050)

    Published 2023
    Save to List
    Saved in:
  10. 90
    Traits at cellular, leaf, and whole-plant scales which were significantly different [increased (↑) or decreased (↓)] or non-significant between tolerant and sensitive cultivars in the N-deficient treatment.

    Traits at cellular, leaf, and whole-plant scales which were significantly different [increased (↑) or decreased (↓)] or non-significant between tolerant and sensitive cultivars in... by Ranjeeta Adhikari (9905958)

    Published 2023
    Save to List
    Saved in:
  11. 91
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 92
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 93
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 94
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 95
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 96
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 97
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 98
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 99
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 100
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: